NSCLC (Non-Small Cell Lung Cancer) is one of the most common forms of lung cancer. In the last several decades, there have been many advancements in the treatment of the disease, especially through the development of targeted therapies, which target specific genetic changes that occur in the cancer cells. Understanding NSCLC, causes of NSCLC, symptoms of NSCLC, and potential NSCLC treatments would be of great advantage to the patients and their families.
What Is Non-Small Cell Lung Cancer?
NSCLC is caused due to the uncontrolled growth of abnormal cells in the lungs. There are many sub-types of NSCLC such as adenocarcinoma and squamous cell carcinoma. It is generally slower to progress than other forms of lung cancer which making it difficult to diagnose.
What Causes Non-Small Cell Lung Cancer?
NSCLC is usually associated with various risk factors. Smoking is the most typical one, but it is not the only one. It is possible for even those individuals who do not smoke at all to suffer from this problem. Some various factors also cause the disease, such as:
- Cigarette smoke
- Environmental pollution
- Hazardous chemicals
- Genetic mutations
What Are The Common Symptoms of NSCLC?
Initially, NSCLC does not have clear symptoms making its detection difficult. However, as the disease advances, the following symptoms may emerge:
● Coughing
● Pain in the chest area
● Difficult breathing
● Feeling fatigued
● Unexpected weight loss
● Blood in the sputum
Detecting the above symptoms on time is important for the early treatment of NSCLC.
How Is NSCLC Diagnosed?
There are a variety of tests that can be done to diagnose non-small cell lung cancer. The important diagnostic tests include the following:
CT Scan: Used to find any abnormality within the lungs by x-rays.
Biopsy: Used to confirm cancerous cells within the body by taking a small sample of tissue or cells from the body.
Gene Mutations: Used to detect any gene mutation.
What is Targeted Therapy for NSCLC?
There have been changes in the treatment of NSCLC since the introduction of targeted therapy. While other treatments affect SEVERAL cell undergoing rapid division, this treatment only targets the mutation of genes responsible for the development of cancer cells. Patients whose mutations include ALK or EGFR respond best to these therapies as they inhibit the signals allowing cancer cells to develop.
Why Testing Is Important Before Treatment?
Before beginning treatment, it is important to conduct molecular testing. This will enable the doctors to know the specific type of mutation that is present in the cancerous cells, therefore selecting the most appropriate form of treatment. Failure to conduct molecular testing can render the treatment ineffective.
Which medicines treat NSCLC?
The use of targeted drugs is important in NSCLC patients since they act directly on the gene mutation existing in the cancer cells. Identify the following targeted medicines which are mostly prescribed by the doctors:
1. Alectinib
Alectinib is the standard medication for ALK-positive NSCLC. It acts on pathways that facilitate tumor growth and progression.
Brand:
ALECENSA 150mg capsule
ALECNIB 150mg capsule
Benefits:
- The medicine slows down the growth of cancer.
- It is specific to particular cancer cells.
- Works for treatment of metastases in the brain.
- Makes treatment more effective.
- The therapy helps postpone disease progression.
- It promotes quality of life during treatment.
- Tends to be more long-lasting than some treatments.
Side effects to be noticed:
- Tiredness
- Muscle discomfort
- Constipation
- Swelling
2. Mobocertinib
Mobocertinib medication was developed for patients with particular EGFR exon 20 insertions mutation, which are difficult to manage with other means.
Brand:
EXKIVITY 40mg, MOBOXEN 40mg
Benefits:
- Medicine act on rare and resistant mutations.
- It aids in slowing down the growth of cancer cells.
- Acts as a choice where others are not available.
- The therapy provides a more individualized treatment plan.
- Is helpful where other methods prove less effective.
- Aids in achieving good disease control in advanced cases.
- Increases the progression-free survival period.
Side Effects:
- Diarrhea
- Skin issues
- Nausea
- Loss of appetite
What is the Future of Precision Medicine in Lung Cancer?
The future of the treatment of NSCLC lies in the advent of precision medicine. Through constant research, there will be new treatments that will target the cancer cells specifically while at the same time reducing side effects. However, new discoveries in genetic testing have made it possible for patients to get customized treatment plans.
Conclusion
NSCLC is a life-threatening disease; however, new developments in the field of targeted treatment have significantly improved the situation. Timely diagnosis, accurate assessment, and personalized treatment are essential factors for better results. With the current developments in precision medicine, patients can now get treatment that is more effective and customized compared to previous years.
FAQs
1. Would the targeted therapy be useful for everybody?
Not really, since these therapies would only work for people who have certain mutations. Tests would be needed to check their eligibility.
2. How long should the treatment going of NSCLC?
It all depends on the stage of cancer and the patient’s reaction to the treatment. Sometimes, the patients would require prolonged treatment.
References
- Osmani, L., Askin, F., Gabrielson, E., & Li, Q. K. (2018, October). Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. In Seminars in cancer biology (Vol. 52, pp. 103-109). Academic Press. https://pmc.ncbi.nlm.nih.gov/articles/PMC5970946/
- Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., … & Rosell, R. (2015). Non-small-cell lung cancer. Nature reviews Disease primers, 1(1), 15009. https://www.mdpi.com/2072-6694/16/4/716
- Wu, Y. L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., … & Solomon, B. J. (2024). Alectinib in resected ALK-positive non–small-cell lung cancer. New England Journal of Medicine, 390(14), 1265-1276. https://europepmc.org/article/MED/38598794/
- Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S. W., Yang, J. C. H., Riely, G. J., … & Jänne, P. A. (2021). Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA oncology, 7(12), e214761.https://pmc.ncbi.nlm.nih.gov/articles/PMC8517885/
- Vargas, A. J., & Harris, C. C. (2016). Biomarker development in the precision medicine era: lung cancer as a case study. Nature reviews cancer, 16(8), 525-537. https://pubmed.ncbi.nlm.nih.gov/27388699/
